title: CD200 is a new prognostic factor in multiple myeloma.
abstract: Using Affymetrix microarrays, we identified the expression of the CD200 gene in multiple myeloma cells (MMCs) of 112 patients with newly diagnosed multiple myeloma (MM). The CD200 gene was either absent or present (Affymetrix call) in 22% and 78% of MMCs, respectively. The CD200 gene is not expressed in cells of the patients' bone marrow (BM). CD200 is a membrane glycoprotein that imparts an immunoregulatory signal through CD200R, leading to the suppression of T-cell-mediated immune responses. Patients with CD200(absent) MMCs have an increased event-free survival (EFS; 24 months) compared with patients with CD200(present) MMCs (14 months), after high-dose therapy and stem cell transplantation. In a Cox proportional-hazard model, the absence or presence of CD200 expression in MMCs is predictive for EFS for patients independently of ISS stage or beta2M serum levels. Thus, CD200 is an independent prognosis factor for patients with MM that could represent a new therapeutic target in MM.
authors.affiliation: Centre Hospitalier Universitaire (CHU) Montpellier, Department of Hematology and Clinical Oncology and Institute of Research in Biotherapy, Montpellier, France.
authors.forename: Jerome
authors.initials: J
authors.lastname: Moreaux
authors.forename: Dirk
authors.initials: D
authors.lastname: Hose
authors.forename: Thierry
authors.initials: T
authors.lastname: Reme
authors.forename: Eric
authors.initials: E
authors.lastname: Jourdan
authors.forename: Michael
authors.initials: M
authors.lastname: Hundemer
authors.forename: Eric
authors.initials: E
authors.lastname: Legouffe
authors.forename: Philippe
authors.initials: P
authors.lastname: Moine
authors.forename: Philippe
authors.initials: P
authors.lastname: Bourin
authors.forename: Marion
authors.initials: M
authors.lastname: Moos
authors.forename: Jill
authors.initials: J
authors.lastname: Corre
authors.forename: Thomas
authors.initials: T
authors.lastname: Möhler
authors.forename: John
authors.initials: J
authors.lastname: De Vos
authors.forename: Jean Francois
authors.initials: JF
authors.lastname: Rossi
authors.forename: Hartmut
authors.initials: H
authors.lastname: Goldschmidt
authors.forename: Bernard
authors.initials: B
authors.lastname: Klein
mesh_terms: D015703:Antigens, CD / Q000096:biosynthesis* / Q000235:genetics; D014408:Biomarkers, Tumor / Q000096:biosynthesis* / Q000235:genetics; D001854:Bone Marrow Cells / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D020869:Gene Expression Profiling / Q000379:methods; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects / Q000235:genetics; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods; D011237:Predictive Value of Tests; D011379:Prognosis
chemical_list: D015703:Antigens, CD; D014408:Biomarkers, Tumor; C042739:antigens, CD200